Navigation Links
Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
Date:10/21/2008

Large-Scale Rapid Production, Increased Bioavailability

MOUNTAIN VIEW, Calif., Oct. 21 /PRNewswire/ -- An increased number of diseases that are either incurable or difficult to treat allures clinicians to the approach of stem cell therapy. Highly prized, due to their therapeutic potential, stem cell therapies are believed to treat a wide variety of diseases. Stem cell research progresses at a fast pace; however, both adult and embryonic stem cells have their own unique challenges that must be overcome before therapies make it to the market.

New analysis from Frost & Sullivan (http://www.pharmaceuticals.frost.com), U.S. Stem Cell Market - Current Developments, provides insights and analysis on stem cell therapeutic development in the U.S., including the clinical trial pipeline, key market drivers and challenges, and the market potential for stem cell therapy in selected disease indications. In this research, Frost & Sullivan's expert analysts thoroughly examine this cutting-edge healthcare technology market.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of U.S. Stem Cell Market - Current Developments, please send an e-mail to Johanna Haynes, Corporate Communications, at johanna.haynes@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

"New research into stem cell therapies has resulted in several technological innovations that have improved the manufacturing and design of these products," notes Frost & Sullivan Research Analyst Katheryn Symank. "For example, improvements in cell sorting and cell culture have allowed for improved survival and growth of adult stem cells. This allows for the rapid production of a high-quality adult stem cell product with increased bio-availability that may be produced on a large scale."

Adult stem cell therapies were traditionally thought to have poor therapeutic potential because they could only be produced in limited quantities or as needed. Now adult stem cells have the potential to become standardized pre-made therapies that can be mass produced.

However, both stem cell types have challenges and technical difficulties that impede product development. Embryonic stem cells, while hailed for their promise as potential therapies, are immersed in both political and ethical controversy. In addition, some researchers have questioned the safety of embryonic stem cells in humans, while adult stem cells require a high degree of technical expertise because they are difficult to culture and lose potency over time.

"Both embryonic stem cells and adult stem cells have their own challenges that must be overcome," explains Symank. "The controversy surrounding embryonic stem cells has resulted in severe limitations in federal funding for their research, while adult stem cells are often viewed as having less therapeutic potential because they can differentiate into a limited number of cells."

New evidence suggests that adult stem cells may actually have more plasticity than once thought, and may actually derive more tissue types. In addition, new technical innovations allow for adult stem cells to be cultured in large quantities without the loss of potency. In regards to embryonic stem cells, despite the severe limitations in federal funding, support from private sources and individual states have allowed research to progress at a fast pace. However, there have been concerns over the safety of the use of embryonic stem cells in humans because of potential adverse consequences from undifferentiated cells.

"In order to ensure the safety of embryonic stem cell products in humans, strict manufacturing regulations may need to be imposed by the FDA," advises Symank. "In addition, there could be strict product safety testing in place to guarantee their safety."

U.S. Stem Cell Market: Current Developments is part of the Pharmaceuticals and Biotechnology subscription, which also includes research in the following markets: Biopharmaceuticals, Specialty Pharmaceuticals, Contract Research and Manufacturing, Vaccines, and Drug Delivery. Recent titles include: U.S. Biotechnology - Therapeutic Monoclonal Antibodies Market, U.S. Contract Research Outsourcing Market, European Biosimilars Market Outlook and U.S. Human Growth Hormone Market. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting, and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates, and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com.

Contact:

Johanna Haynes

Corporate Communications - North America

P: 210.247.3870

F: 210.348.1003

E: johanna.haynes@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
2. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
3. Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry
4. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
5. Atrium Innovations Announces Management Changes
6. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
7. Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures
8. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
9. Mediatech Moves to Prince William County Innovation Park
10. The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus
11. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 25, 2017 , ... Throughout this webinar, participants will ... process development and economic goals were achieved in both industry and academic settings. ... system, along with techniques for scaling production of mesenchymal stem cells (MSCs) and ...
(Date:5/24/2017)... BOUNTIFUL, Utah (PRWEB) , ... May 24, 2017 ... ... announces the selection and implementation of CLEARAS Water Recovery’s Advanced Biological Nutrient Recovery ... a key component of a $24 million plant upgrade to sustainably meet current ...
(Date:5/24/2017)... May 23, 2017 As Ebola resurfaces in the ... deaths and 20 suspected cases now reported, a new analysis ... database, showed a correlation between the 2014 and 2017 outbreaks ... rose sharply in 2012-13, which preceded the 2014 outbreak. An ... Ebola gene Replikin counts in 2014-15, which again precedes the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a ... anniversary, marking the occasion with a strong presence at Bio-IT World Conference & ... further extends an invitation to all attendees to view posters on the ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):